Marshall Glesby, MD
Infectious Disease · New York, NYNPI 1396891644
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,250 of the $2,250 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Regeneron.
Across 1 payment — averaging $2250.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$2K
Across 7 payments — averaging $66,886 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$418K
- Gilead$49K
- Swedish Orphan Biovitrum AB$1K
What the payments were for
- Consulting fees$2,250100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 1 | $2,250 |
How this compares
$2,250 in reported general payments places this provider in the 80th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TivicayDolutegravir Sodium | 62 | $141,469 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 25 | $93,747 |
| DescovyEmtricitabine/Tenofov Alafenam | 31 | $68,257 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $60,905 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 14 | $57,265 |
| NorvirRitonavir | 12 | $3,110 |
| ValacyclovirValacyclovir Hcl | 17 | $1,250 |
| Oxycodone Hcl | 12 | $670 |
| FenofibrateFenofibrate,micronized | 11 | $512 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $306 |
| Valsartan | 14 | $210 |
| Atorvastatin Calcium | 37 | $172 |
| Rosuvastatin Calcium | 15 | $116 |
| Amlodipine Besylate | 32 | $85 |
| Lisinopril | 28 | $83 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in New York
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Genovefa PapanicolaouNew York$209K
- Michelle CespedesNew York$125K
- Donald KaminskyNew York$120K
- Judith AbergNew York$104K
- Thomas WalshNew York$98K
- Stuart HaberNew York$73K
- Michael GaisaNew York$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.